BRIDGEWATER, N.J., Oct. 4, 2024
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first
global biopharmaceutical company striving to deliver first- and
best-in-class therapies to transform the lives of patients facing
serious diseases, today announced the granting of inducement awards
to 52 new employees. In accordance with NASDAQ Listing Rule
5635(c)(4), the awards were approved by Insmed's Compensation
Committee and made as a material inducement to each employee's
entry into employment with the Company.
In connection with the commencement of their employment, the
employees received options on October 1,
2024 to purchase an aggregate 106,160 shares of Insmed
common stock at an exercise price of $72.88 per share, the closing trading price on
the Nasdaq Global Select Market on the date of grant.
The options have a 10-year term and a four-year vesting
schedule, with 25% of the shares subject to the option vesting on
the first anniversary of the relevant grant date and 12.5% of the
shares subject to the option vesting every six months thereafter
through the fourth anniversary of the relevant grant date, subject
to the relevant employee's continued service with Insmed on the
applicable vesting date.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical
company striving to deliver first- and best-in-class therapies to
transform the lives of patients facing serious diseases. The
Company is advancing a diverse portfolio of approved and mid- to
late-stage investigational medicines as well as cutting-edge drug
discovery focused on serving patient communities where the need is
greatest. Insmed's most advanced programs are in pulmonary and
inflammatory conditions, including a therapy approved in the
United States, Europe, and Japan to treat a chronic,
debilitating lung disease. The Company's early-stage research
programs encompass a wide range of technologies and modalities,
including gene therapy, AI-driven protein engineering, protein
manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater, New
Jersey, Insmed has offices and research locations throughout
the United States, Europe, and Japan. Insmed is proud to be recognized as one
of the best employers in the biopharmaceutical industry, including
spending three consecutive years as the No. 1 Science Top
Employer. Visit www.insmed.com to learn more.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor
Relations
Insmed
(646)
812-4030
bryan.dunn@insmed.com
Media:
Mandy Fahey
Vice President, Corporate
Communications
Insmed
(732)
718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302266891.html
SOURCE Insmed Incorporated
